9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Mesothelioma

Estimated Enrollment: 82

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Progression-free survival (PFS) rate at 18 weeks,  Overall objective response rate,  Symptomatic response rate, Safety as measured by NCI CTCAE v3.0 and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire

Interventions: bortezomib, cisplatin

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: April 2010

Completion Date: March 2012

Last  Posted Date: July 12, 2018

Location: Royal Marsden – Surrey, Sutton, England, United Kingdom

Website Link: https://ClinicalTrials.gov/show/NCT00458913

Was this article helpful?
Dislike 0